IPR2017-00807 - Argentum Pharmaceuticals LLC v. Cipla Ltd

Details
PATENT NUMBER
8168620 Medical
APPL. NUMBER
10518016
PETITIONER
Argentum Pharmaceuticals LLC
Large Operating Company
PATENT OWNER
Cipla Ltd
Operating Company
STATUS
Settlement
FILING DATE
2017-02-02
INSTITUTION DATE
2017-08-21
TERMINATION DATE
2018-05-21
PET. COUNSEL
Foley & Lardner LLP
Argentum Pharmaceuticals LLC
P.O. COUNSEL
Sterne, Kessler, Goldstein & Fox PLLC
AUTHOR JUDGE
Timeline
Petition
Notice of Filing Date
Preliminary Response
Institution Decision
Request for Rehearing
Request for Rehearing
Rehearing Decision
Rehearing Decision
Motion to Terminate
Final Decision
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2018
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2019
Feb
Mar
Apr
May
Jun
Jul
Docket
Paper No.
Date
Party
Type
Name
12017-02-02PetitionerPower of AttorneyPetitioner Power of Attorney
22017-02-02PetitionerPetitionPetition
10012017-02-02PetitionerU.S. Patent No. 8,168,620
10022017-02-02PetitionerProsecution History of U.S. Patent No. 8,168,620 (Part 2 of 2)
10032017-02-02PetitionerDeclaration of Dr. Robert Schleimer
10042017-02-02PetitionerDeclaration of Dr. Maureen Donovan
10052017-02-02PetitionerMeda Pharms. Inc. v. Apotex Inc.
10062017-02-02PetitionerUK Patent Application GB 0213739.6
10072017-02-02PetitionerU.S. Patent No. 5,164,194
10082017-02-02PetitionerAstelin Label
10092017-02-02PetitionerU.S. Patent No. 4,335,121
10102017-02-02PetitionerFlonase Label
10112017-02-02PetitionerEuropean Patent Application No. 0780127
10122017-02-02PetitionerPCT Publication No. WO 98/48839
10132017-02-02PetitionerBritish Pharmaceutical Codex
10142017-02-02PetitionerU.S. Patent Publication No. 20040136918
10152017-02-02PetitionerFalser, N., et al.
10162017-02-02PetitionerKusters, S., et al.
10172017-02-02PetitionerStellato, C., et al.
10182017-02-02PetitionerJohnson, M.
10192017-02-02PetitionerDykewicz, Mark S., et al.
10202017-02-02PetitionerStoloff, R., et al.
10212017-02-02PetitionerBerger, W. E. et al.
10222017-02-02PetitionerCauwenberge, P. et al.
10232017-02-02PetitionerSpector, S.
10242017-02-02PetitionerBousquet et al.
10252017-02-02PetitionerMarkham, A., et al.
10272017-02-02PetitionerAnsel, et al.
10302017-02-02PetitionerAdvair Diskus Prescribing Information
10312017-02-02PetitionerJuniper, E
10332017-02-02PetitionerWade & Weller
10342017-02-02PetitionerRatner, P., et al. (1998)
10352017-02-02PetitionerDrouin, M., et al.
10362017-02-02PetitionerSimpson, R.
10382017-02-02PetitionerBrooks, C. et al.
10392017-02-02PetitionerJuniper, E F
10402017-02-02PetitionerBenincasa, C. & Lloyd, R.S.
10412017-02-02PetitionerGalant, S. and Wilkinson, R.
10422017-02-02PetitionerSchleimer, R.
10452017-02-02PetitionerRatner, Paul H., et al. (2008)
10462017-02-02PetitionerIMITREX Prescribing Information
10472017-02-02PetitionerNASACORT AQ Prescribing Information
10482017-02-02PetitionerRabago, David, et al.
10492017-02-02PetitionerBudavari, S., et al.
10502017-02-02PetitionerRatner (1994)
10512017-02-02PetitionerCurriculum Vitae of Dr. Robert Schleimer
10522017-02-02PetitionerCurriculum Vitae of Dr. Maureen Donovan
10532017-02-02PetitionerPatent Certification for U.S. Patent No. 5,164,194 - Astelin Nasal Spray (2000)
10542017-02-02PetitionerAvicel RC-591
32017-02-23Potential Patent OwnerPower of AttorneyCipla Limited's Power of Attorney
42017-02-23Potential Patent OwnerMandatory NoticeCipla Limited's Mandatory Notices
52017-02-28BoardNotice of Filing DateNotice of Accord Filing Date
62017-05-30Potential Patent OwnerCipla Ltd.'s Exhibit List
72017-05-30Potential Patent OwnerPreliminary ResponseCipla Ltd.'s Patent Owner Preliminary Response
82017-05-30Potential Patent OwnerOtherPatent Owner Cipla Limited's Motion for Pro Hac Vice Admission of Uma N. Everett Under 37 CFR ¿¿ 42.10(c)
20012017-05-30Potential Patent OwnerWarner Carr, M.D. Declaration
20022017-05-30Potential Patent OwnerWarner Carr, M.D. Curriculum Vitae
20032017-05-30Potential Patent OwnerAlexander Dominic D'Addio, Ph.D. Declaration
20042017-05-30Potential Patent OwnerAlexander Dominic D'Addio, Ph.D. Curriculum Vitae
20052017-05-30Potential Patent OwnerJohn C. Jarosz Declaration
20062017-05-30Potential Patent OwnerJohn C. Jarosz Curriculum Vitae
20072017-05-30Potential Patent OwnerHugh David Charles Smyth, Ph.D. Declaration
20082017-05-30Potential Patent OwnerHugh David Charles Smyth, Ph.D. Curriculum Vitae
20092017-05-30Potential Patent OwnerComplaint for Patent Infringement, December 2, 2014, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-UNA (D. Del.)
20102017-05-30Potential Patent OwnerComplaint for Patent Infringement, September 9, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Perrigo UK Finko Limited Partnership, Perrigo Company and Perrigo Pharmaceuticals Co., Case No. 1:16-cv-00794-LPS (D. Del.)
20112017-05-30Potential Patent OwnerExpert Report of Robert P. Schleimer, Ph.D., August 19, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20122017-05-30Potential Patent OwnerExpert Rebuttal Report of Robert P. Schleimer, Ph.D., July 29, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20132017-05-30Potential Patent OwnerExpert Reply Report of Robert P. Schleimer, Ph.D., August 19, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20142017-05-30Potential Patent OwnerDr. Maureen Donovan Deposition transcript, October 7, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20152017-05-30Potential Patent OwnerExpert Report of Maureen D. Donovan, Ph.D., June 30, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20162017-05-30Potential Patent OwnerExpert Reply Report of Maureen D. Donovan, Ph.D., August 19, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20172017-05-30Potential Patent OwnerPublicly Filed Proposed Joint Pretrial Order, November 10, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D.I.137) (Redactions in Original)
20182017-05-30Potential Patent OwnerBench Trial Transcript, Volume A, December 13, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20192017-05-30Potential Patent OwnerBench Trial Transcript, Volume B, December 14, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20202017-05-30Potential Patent OwnerBench Trial Transcript, Volume C, December 15, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20212017-05-30Potential Patent OwnerBench Trial Transcript, Volume D, December 16, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20222017-05-30Potential Patent OwnerPlaintiffs' Proposed Findings of Fact, January 10, 2017, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 155)
20232017-05-30Potential Patent OwnerDefendants' Proposed Finding of Facts, January 10, 2017, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 156)
20242017-05-30Potential Patent OwnerDefendants' Opening Post-Trial Brief, January 24, 2017, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 158)
20252017-05-30Potential Patent OwnerDr. Robert Schleimer Deposition transcript, September 29, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.)
20262017-05-30Potential Patent OwnerGennaro, A. R. Remington's Pharmaceutical Sciences (17th ed., 1985), Ch. 80: 1455-1477; Ch. 82: 1478-1491; Ch. 84:1492-1517
20272017-05-30Potential Patent OwnerAccolate Approval Letter and Label, Application Number 20-547/S011, Zeneca Pharmaceuticals
20282017-05-30Potential Patent OwnerAvomeen Analytical Services Report, June 30, 2016 (PTX0129)
20292017-05-30Potential Patent OwnerExpert Report of Dr. Matthew J. Herpin and Corresponding Documents (PTX1663)
20302017-05-30Potential Patent OwnerExpert Report of Dr. Govindarajan and Corresponding Documents (PTX1664)
20312017-05-30Potential Patent OwnerDuonase Imitator Product Labels (PTX0026)
20322017-05-30Potential Patent OwnerAllegra-D Approval Letter, Application Number 20786, Approved December 24, 1997, (PTX0126)
20342017-05-30Potential Patent OwnerPhysicians' Desk Reference, 54th ed., pp. 1343-1344, 2404-2406, 2781-2783 (2000)
20352017-05-30Potential Patent OwnerRiordan, John. An Introduction to Combinatorial Analysis (1958), Ch. 1: 1-18
20362017-05-30Potential Patent OwnerZyrtec-D FDA Label, Approved August 10, 2001
20372017-05-30Potential Patent OwnerArgentum Pharmaceuticals Website, accessed May 17, 2017
20382017-05-30Potential Patent OwnerKhan 2000 (PTX0194)
20392017-05-30Potential Patent OwnerFlonase¿¿ Label 1998 (PTX0059)
20402017-05-30Potential Patent OwnerBritish Pharmaceutical Codex 1973 (PTX0193)
20412017-05-30Potential Patent OwnerHowarth 2000 (PTX0337)
20422017-05-30Potential Patent OwnerNielsen 2001 (PTX0338)
20432017-05-30Potential Patent OwnerShenfield 1986 (DTX-048)
20442017-05-30Potential Patent OwnerMichael 2001 (PTX0179)
20452017-05-30Potential Patent OwnerHampel 2010 (PTX0230)
20462017-05-30Potential Patent OwnerWeiler 1997 (PTX0329)
20472017-05-30Potential Patent OwnerBlaiss 2001 (PTX0058)
20482017-05-30Potential Patent OwnerDataMonitor, July 2010 (PTX0396)
20492017-05-30Potential Patent Owner2006 Cipla-Meda License Agreement with Quality Agreement (PTX1016)
20502017-05-30Potential Patent Owner2011 First Amendment to Cipla-Meda Agreement (PTX0282)
20512017-05-30Potential Patent OwnerPhysicians' Desk Reference, 54th ed., pp. 2783- 2786 (2000)
20522017-05-30Potential Patent OwnerLeung 2012 (PTX0029)
20532017-05-30Potential Patent OwnerGlobal Data September 2015 (PTX0397)
20542017-05-30Potential Patent OwnerAstelin¿¿ Day Life CyclePlan November 2002 (PTX1005)
20552017-05-30Potential Patent OwnerMedPointe Product & Process Development Program Priorities and Issues September 2002 (PTX0143)
20562017-05-30Potential Patent OwnerAstelin¿¿ Nasal Spray Life Cycle Management Projects (Preliminary Plan) (PTX1006)
20572017-05-30Potential Patent Owner2006.02.06 Email from Paul Edick to Dennis Fuge re: Pfeiffer Bi Dose Nasal Spray System (PTX0149)
20582017-05-30Potential Patent Owner2006.03.21 Email and attachment from Kalidas Kale to Alex D'Addio re: Astelin ¿¿¿ Flonase Combination Product Feasibility Assessment Plan (PTX0151)
20592017-05-30Potential Patent OwnerU.S. Patent No. 8,071,073
20602017-05-30Potential Patent OwnerU.S. Patent No. 8,518,919
20612017-05-30Potential Patent OwnerMedPointe Laboratory Notebook No. 1044 - Excerpts (PTX0142)
20622017-05-30Potential Patent OwnerIMS data for U.S. allergic rhinitis products, 01.2012-04.2016 (PTX0929)
20642017-05-30Potential Patent Owner2011.11.02 Email and attachment from Ashwini Dumaswala to Bryan Roecklein re: 2012 Dymista¿¿ Strategic Plan (PTX1118)
20652017-05-30Potential Patent OwnerAll Products - Apotex Products: United States, accessed June 22, 2016
20662017-05-30Potential Patent OwnerDymista¿¿ Prescribing Information 2015 (PTX0024)
20672017-05-30Potential Patent OwnerDrug Approval Package: Dymista¿¿, Approved May 1, 2012 (PTX0392)
20682017-05-30Potential Patent OwnerMeda AB Interim Report Jan.-Sept. 2012 (PTX0393)
20692017-05-30Potential Patent OwnerCipla Website, accessed June 28, 2016 (PTX0379)
20702017-05-30Potential Patent OwnerDuonase Nasal Spray ¿¿¿ Prescribing Information (PTX0134)
20712017-05-30Potential Patent OwnerCipla Website,accessed June 28, 2016 (PTX0380)
20722017-05-30Potential Patent OwnerIMS data for Duonase competitor products, 2005-2016 (PTX0816)
20732017-05-30Potential Patent OwnerDymista¿¿ briefing document (PTX1654)
20742017-05-30Potential Patent Owner2014.11.14 Email and attachment from Stuart Loeschto Betsy Orrison re: Dymista¿¿ US Marketing Plan 2015 (PTX0271)
20752017-05-30Potential Patent OwnerDymista¿¿ Competitor Benchmarking Presentation 2012 (PTX0926)
20762017-05-30Potential Patent OwnerMeda ¿¿¿ 2016 Dymista¿¿ Brand Plan (PTX0406)
20772017-05-30Potential Patent Ownerfda.gov,"Prescription to Over-the-Counter (OTC) Switch List," accessed June 28, 2016 (PTX0407)
20782017-05-30Potential Patent OwnerJohnson & Johnson Press Release,"RHINOCORT¿¿ Allergy Spray Now Available Over The Counter Nationally," dated February 8, 2016
20792017-05-30Potential Patent Owner2011.11.02 Email and attachment from Ashwini Dumaswala to Bryan Roecklein re: 2012 Dymista¿¿ Strategy Plan (PTX0267)
20802017-05-30Potential Patent OwnerMEDA Presentation (2001) (PTX0871)
20812017-05-30Potential Patent OwnerFDA.gov, "First-Time Generic Drug Approvals - March 2016," (accessed June 28, 2016) (PTX0424)
20822017-05-30Potential Patent OwnerRenavatio Presentation & Meda Presentation (PTX0426)
20832017-05-30Potential Patent OwnerTransmittal of advertisements and promotional labeling to the U.S. Food and Drug Administration for Dymista¿¿, June 17, 2015 (PTX0914)
20842017-05-30Potential Patent OwnerTransmittal of advertisements and promotional labeling to the U.S. Food and Drug Administration for Dymista¿¿, June 16, 2015 (PTX0916)
20852017-05-30Potential Patent OwnerTransmittal of advertisements and promotional labeling to the U.S. Food and Drug Administration for Dymista¿¿, November 26, 2012 (PTX0917)
20862017-05-30Potential Patent OwnerTransmittal of advertisements and promotional labeling to the U.S. Food and Drug Administration for Dymista¿¿, June 29, 2015 (PTX0915)
20872017-05-30Potential Patent OwnerCipla Duonase Marketing Presentation (PTX0315)
20882017-05-30Potential Patent OwnerMeda/Cipla Powerpoint ¿¿¿ Complete Picture (PTX0412)
20892017-05-30Potential Patent Ownerhealthcare.utah, "The Difference Between AR and Sinusitis," accessed June 28, 2016 (PTX0429)
20902017-05-30Potential Patent OwnerFamily Allergy & Asthma Care of Montana Website, accessed June 28, 2016 (PTX0430)
20912017-05-30Potential Patent OwnerBousquet "Allergic Rhinitis," accessed June 28, 2016 (PTX0431)
20922017-05-30Potential Patent OwnerSamuelson and Nordhaus 2010 (PTX0415)
20932017-05-30Potential Patent OwnerDymista¿¿ Marketing Plan 2016 (PTX0438)
20942017-05-30Potential Patent OwnerDymista¿¿ Formulary Coverage Powerpoint 2014 (PTX0892)
20952017-05-30Potential Patent OwnerMeda Memorandum re: CVS Caremark Formulary Decisions 2015 (PTX0447)
20962017-05-30Potential Patent OwnerBagwell 2007 (PTX0432)
20972017-05-30Potential Patent OwnerChing 2010 (PTX0433)
20982017-05-30Potential Patent OwnerBerndt 2001 (PTX0434)
20992017-05-30Potential Patent OwnerBloomberg Website, accessed May 19, 2017
21002017-05-30Potential Patent OwnerNewsroom Website accessed May 19, 2017
21012017-05-30Potential Patent OwnerApotex Press Release "Apotex Launches First Generic Version of Merck's Nasonex¿¿," dated March 24, 2016
21032017-05-30Potential Patent OwnerThe United States Pharmacopeia 1999 (PTX0188)
21042017-05-30Potential Patent OwnerLieberman 1996 (PTX0177)
21052017-05-30Potential Patent OwnerShin Etsu Pharmacoat USP Hypromellose Brochure (2005) (PTX0186)
21072017-05-30Potential Patent OwnerGennaro 2000 (PTX0184)
21102017-05-30Potential Patent OwnerKibbe 2000 (PTX0198)
21112017-05-30Potential Patent OwnerMichael 2000 (PTX0180)
21122017-05-30Potential Patent OwnerAllen 1998 (PTX0167)
21132017-05-30Potential Patent OwnerLieberman 1996 (PTX0192)
21142017-05-30Potential Patent OwnerMeda Highlights of Prescribing Information 2015 (PTX0154)
21202017-05-30Potential Patent OwnerMedPointe Product & Process Development, Program Priorities and Issues - November 18, 2002, "Commercial Product Technical Support" (PTX0144)
21212017-05-30Potential Patent Owner2006.02.06 Email from Richard Spivey to Alex D'Addio re: Pfeiffer Bi Dose Nasal Spray System (PTX0150)
21222017-05-30Potential Patent Owner2003.11.11 Email and attachment from Mary Lehr to Gul Balwani (PTX0255)
21232017-05-30Potential Patent OwnerIMS data for Indian allergic rhinitis nasal spray products, December 2010-December 2014 (PTX0823)
21242017-05-30Potential Patent OwnerIMS data for Indian allergic rhinitis nasal sprays products, March 2013 ¿¿¿ March 2017
21262017-05-30Potential Patent OwnerIMS data for Duonase competitor products, 2005-2017
21272017-05-30Potential Patent Owner2017.03.21 Email from Mike Houston to Adam LaRock re IPR2017-00807
21292017-05-30Potential Patent OwnerCenter for Drug Evaluation and Research 2000 (PTX0025)
21302017-05-30Potential Patent Ownerwebmd.com, "FDA Oks Generic Version of Flonase," accessed May 26, 2017
21312017-05-30Potential Patent Owner"What is a Tiered Formulary and What Does it Mean for Me?," accessed May 26, 2017
21322017-05-30Potential Patent OwnerIMS data for U.S. allergic rhinitis products, May 2011 - April 2017
21332017-05-30Potential Patent OwnerBousquet 2001 (PTX0326)
21342017-05-30Potential Patent OwnerMemorandum Opinion, May 12, 2016, Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp., Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 114)
21352017-05-30Potential Patent OwnerWade and Weller 1994
21362017-05-30Potential Patent OwnerTalbot 1997
21382017-05-30Potential Patent OwnerDataMonitor ¿¿¿ "Commercial and Stakeholder Perspectives: Allergic Rhinitis," September 2004 (PTX0098)
21392017-05-30Potential Patent OwnerAffidavit in Support of Motion for Pro Hac Vice Admission of Uma N. Everett
21402017-05-30Potential Patent OwnerDeclaration of Adam C. LaRock
92017-06-02Potential Patent OwnerOtherPatent Owner's Updated Mandatory Notices
102017-06-08BoardOtherOrder Granting Patent Owner Motion for Pro Hac Vice Admission of Uma N. Everett
112017-08-21BoardInstitution DecisionTrial Instituted Document
122017-08-21BoardOtherScheduling Order
132017-09-05PetitionerRequest for RehearingPetitioner's Request for Rehearing
142017-09-05Potential Patent OwnerOtherCipla Limited's Objections to Evidence
152017-09-05Potential Patent OwnerRequest for RehearingCipla Limited's Request for Rehearing
162017-09-05PetitionerOtherPetitioner's Objections to Evidence
172017-10-05Potential Patent OwnerOtherNotice of Deposition of Robert P. Schleimer, Ph.D.
182017-10-05Potential Patent OwnerOtherNotice of Deposition of Maureen D. Donovan, Ph.D.
192017-10-30BoardRehearing DecisionDenying Petitioners Request for Rehearing 37 C.F.R. sec 42.71(d)
202017-10-31BoardRehearing DecisionDecision - Denying Patent Owner's Request for Rehearing
212017-11-20Potential Patent OwnerResponsePatent Owner Response
222017-11-20Potential Patent OwnerExhibit List
232017-11-20Potential Patent OwnerOtherMotion to Seal
21452017-11-20Potential Patent OwnerUSPN 6,599,914
21462017-11-20Potential Patent OwnerUS Utility 09_841,506
21472017-11-20Potential Patent OwnerSecond Carr Declaration
21482017-11-20Potential Patent OwnerSecond D'Addio Declaration
21492017-11-20Potential Patent OwnerSecond Jarosz Declaration
21562017-11-20Potential Patent OwnerHandbook of Pharmaceutical Excipients 2000
21572017-11-20Potential Patent OwnerHayashi 1999
21582017-11-20Potential Patent OwnerSchleimer Deposition Transcript
21592017-11-20Potential Patent OwnerDonovan Deposition Transcript
21602017-11-20Potential Patent OwnerAmended Default Protective Order
21612017-11-20Potential Patent OwnerBarnes 2001
21622017-11-20Potential Patent OwnerAndy 2002
21632017-11-20Potential Patent OwnerMMIT Dymista Formulary Information
21642017-11-20Potential Patent OwnerSept. 7, 2007 FDA Letter
21652017-11-20Potential Patent OwnerMay 19. 2008 FDA Letter
21672017-11-20Potential Patent OwnerSherman 1951
21682017-11-20Potential Patent OwnerUpdated Jarosz CV
21692017-11-20Potential Patent OwnerClarinex Label - 2001
21702017-11-20Potential Patent OwnerStorms 1997
21712017-11-20Potential Patent OwnerCipla Duonase Manufacturing Guide - PUBLIC
21722017-11-20Potential Patent OwnerCipla Duonase Manufacturing Guide - PUBLIC
21732017-11-20Potential Patent OwnerDymista Investigation Report
21742017-11-20Potential Patent OwnerDymista NDA Excerpt - PUBLIC
21752017-11-20Potential Patent OwnerCipla Duonase Stability Testing Form - PUBLIC
21762017-11-20Potential Patent OwnerSecond Smyth Declaration - PUBLIC
242018-01-29PetitionerOtherNotice of Deposition - Smyth
252018-01-29PetitionerOtherPetitioner's Updated Mandatory Notice
262018-02-02PetitionerOtherStipulation Concerning Schedule
272018-02-05PetitionerOtherNotice of Deposition - Carr
282018-02-14PetitionerOtherNotice of Deposition - D'Addio
292018-03-06PetitionerOtherPetitioner's Motion to Seal
302018-03-06PetitionerReplyPETITIONER REPLY TO PATENT OWNER RESPONSE
312018-03-06PetitionerPetitioner's Exhibit List of March 6, 2018
10552018-03-06PetitionerDr. Accetta Patient Record (1998)
10562018-03-06PetitionerUS 6,417,206
10572018-03-06PetitionerBusiness Wire
10582018-03-06PetitionerCenter for Drug Evaluation and Research
10592018-03-06PetitionerGlaxoSmithKline
10602018-03-06PetitionerMeda AB
10612018-03-06PetitionerGeneric Astelin
10622018-03-06PetitionerCetirizine & Levocetirizine
10632018-03-06PetitionerFexofenadine
10642018-03-06PetitionerLoratadine & Desloratadine
10652018-03-06PetitionerDurie
10662018-03-06PetitionerMeda, "Annual Report 2015."
10672018-03-06PetitionerMeda, "Annual Report 2014."
10682018-03-06PetitionerMeda, "Annual Report 2013."
10692018-03-06PetitionerPrescription Drug Pricing in the Private Sector
10702018-03-06PetitionerBeclomethasone
10712018-03-06PetitionerSur
10722018-03-06PetitionerBrozek
10732018-03-06Petitioner2010 Top 200 Branded Drugs by Retail Dollars
10742018-03-06PetitionerTop 200 Brand-Name Drugs by Retail Dollars in 2005
10752018-03-06PetitionerGrabowski
10762018-03-06PetitionerMeda, "Annual Report 2012."
10772018-03-06PetitionerDiMasi
10782018-03-06PetitionerSummary Application Review: Application Number 22-203
10792018-03-06PetitionerMeda, "Annual Report 2009."
10802018-03-06Petitioner2010 top 200 Generic Drugs by Total Prescriptions
10812018-03-06PetitionerVoet
10822018-03-06PetitionerShadowen
10832018-03-06PetitionerDymista NDA Approval
10842018-03-06PetitionerCarrier
10852018-03-06PetitionerHerper
10862018-03-06PetitionerPrescription Drug Pricing in the Private Sector
10872018-03-06PetitionerScherer
10882018-03-06PetitionerHow Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry
10892018-03-06PetitionerDanzon
10902018-03-06PetitionerConcepts in Managed Care Pharmacy
10912018-03-06PetitionerDanzon - Health Insurance
10922018-03-06PetitionerABA Section of Antitrust Law
10932018-03-06PetitionerPromotional Spending for Prescription Drugs
10942018-03-06PetitionerScherer
10952018-03-06PetitionerLu
10962018-03-06PetitionerYi
10972018-03-06PetitionerPatwardhan
10982018-03-06PetitionerFugh-Berman
10992018-03-06PetitionerElliott
11002018-03-06PetitionerAllan
11012018-03-06PetitionerShrank
11022018-03-06PetitionerShelley
11032018-03-06PetitionerApotex Corp.
11042018-03-06PetitionerPerrigo
11052018-03-06PetitionerDocGuide.com
11062018-03-06PetitionerApotex Launches First Generic Version of Merck's Nasonex
11072018-03-06PetitionerVaidyanathan
11082018-03-06PetitionerFlunisolide
11092018-03-06PetitionerClaritin-D Drug Approval
11102018-03-06PetitionerNasalide Drug Approval
11112018-03-06PetitionerTraimcinolone
11122018-03-06PetitionerNDC Director - Ticanase
11132018-03-06PetitionerFluticasone Propionate
11142018-03-06PetitionerOlopatadine
11152018-03-06PetitionerBudesonide
11162018-03-06PetitionerMometasone
11172018-03-06PetitionerMahr
11182018-03-06PetitionerParliament of India Report
11192018-03-06PetitionerKataria
11202018-03-06PetitionerBhargava
11212018-03-06PetitionerPfizer India
11222018-03-06Petitioner2010 Top 200 Branded Drugs by Total Prescriptions
11232018-03-06PetitionerBeconase AQ
11242018-03-06PetitionerMcDuff
11252018-03-06PetitionerTidwell
11262018-03-06PetitionerAyalew
11272018-03-06PetitionerWeigmann
11282018-03-06PetitionerGottlieb
11292018-03-06PetitionerMorton
11302018-03-06PetitionerAuthorized Generic Drugs: Short-Term Effects and Long-Term Impact
11312018-03-06PetitionerApotex - Pharmacy Times
11322018-03-06PetitionerCanadian Generic Drug Sector Study
11332018-03-06PetitionerMorton
11342018-03-06PetitionerBhadoria
11352018-03-06PetitionerIndia Pharma Inc.
11362018-03-06PetitionerSalunke
11372018-03-06PetitionerGilbert
11382018-03-06PetitionerLanjouw
11392018-03-06PetitionerCurriculum Vitae of John C. Staines, Jr.
11402018-03-06PetitionerDeclaration of John C. Staines, Jr.
11412018-03-06PetitionerDeposition Transcript of Dr. Alexander Dominic D¿¿¿Addio
11422018-03-06PetitionerDeposition Transcript of Dr. Warner W. Carr
11432018-03-06PetitionerDeposition Transcript of Dr. Hugh David Charles Smyth
11442018-03-06PetitionerSecond Declaration of Dr. Robert Schleimer
11462018-03-06PetitionerDell and Colliopoulos
11472018-03-06PetitionerGREIFF
11482018-03-06PetitionerHan
11492018-03-06PetitionerNairn
11502018-03-06PetitionerRhinolast Nasal Spray
11512018-03-06PetitionerSchmidt
11522018-03-06PetitionerU.S. Patent No. 3,636,200
11532018-03-06PetitionerU.S. Patent No. 5,196,436
11542018-03-06PetitionerU.S. Patent No. 5,658,919
11552018-03-06PetitionerU.S. Patent No. 6,565,832
11562018-03-06PetitionerPCT Publication No. WO01/28563
11572018-03-06PetitionerPatent Assignment
11582018-03-06PetitionerE-mail: February 20, 2018 to March 5, 2018
11592018-03-06PetitionerBerger
11602018-03-06PetitionerCorren
11612018-03-06PetitionerLaForce
11622018-03-06PetitionerBerger
11632018-03-06PetitionerUpdated Curriculum Vitae of Dr. Robert Schleimer
11642018-03-06PetitionerMcNeely
11652018-03-06PetitionerSecond Declaration of Dr. Maureen Donovan (redacted version)
11662018-03-06PetitionerU.S. Patent No. 8,933,060
11672018-03-06PetitionerU.S. Patent No. 8,304,405
11682018-03-06PetitionerKublik
322018-03-13Potential Patent OwnerOtherPatent Owner's Objections to Evidence As Of March 13, 2018
332018-03-20Potential Patent OwnerOther2nd Donovan Deposition Notice
342018-03-20Potential Patent OwnerOther2nd Schleimer Deposition Notice
352018-03-29Potential Patent OwnerOtherStaines Deposition Notice
362018-04-02Potential Patent OwnerOtherStipulation Concerning Schedule
372018-04-09Potential Patent OwnerOtherRequest for Oral Argument
382018-04-09Potential Patent OwnerOtherCipla Ltd.'s Corrected Request for Oral Argument
392018-04-09PetitionerOtherRequest for Oral Argument
402018-04-10BoardOtherORDER Oral Hearing 37 C.F.R. 42.70
412018-04-10PetitionerOtherPetitioner's Motion to Exclude Evidence
422018-04-10PetitionerOtherPetitioner's Exhibit List of April 10, 2018
432018-04-10Potential Patent OwnerOtherMotion to Exclude
442018-04-10Potential Patent OwnerOtherMotion for Observations on Cross Exam
452018-04-10Potential Patent OwnerUpdated Exhibit List
11722018-04-10PetitionerEx. 1172 - email
11732018-04-10PetitionerEx. 1173 - email
21772018-04-10Potential Patent OwnerExhibit from Donovan's Second Deposition
21782018-04-10Potential Patent OwnerSecond Donovan Deposition Transcript
21792018-04-10Potential Patent OwnerSecond Schleimer Deposition Transcript
21802018-04-10Potential Patent OwnerStaines Deposition Transcript
21812018-04-10Potential Patent OwnerEX1171 - Staines Deposition Exhibit 1171
462018-04-24Potential Patent OwnerOtherUpdated Mandatory Notices
472018-04-24Potential Patent OwnerOtherPatent Owner's Opposition to Motion to Exclude
482018-04-24PetitionerOtherOpposition to Patent Owner's Motion To Exclude Evidence
492018-04-24PetitionerOtherResponse to Patent Owner's Motion for Observations
502018-04-24PetitionerPetitioner's Exhibit List of April 24, 2018
10372018-04-24PetitionerEx. 1037
10432018-04-24PetitionerEx. 1043
11702018-04-24PetitionerEx. 1170
11742018-04-24PetitionerEx. 1174
11752018-04-24PetitionerEx. 1175
512018-04-26BoardOtherConduct of the Proceeding
522018-04-30PetitionerOtherPETITIONER¿¿¿S REPLY TO PATENT OWNER¿¿¿S OPPOSITION TO PETITIONER¿¿¿S MOTION TO EXCLUDE
532018-04-30Potential Patent OwnerOtherPatent Owner's Reply to Opposition to Motion to Exclude
542018-05-11Potential Patent OwnerOtherJoint Motion to Limit Petition
552018-05-11Potential Patent OwnerOtherExhibit List
21822018-05-11Potential Patent Owner2182 - Joint Stipulation to Limit Petition under 37 CFR 42.71
562018-05-14PetitionerOtherPetitioner's Objections to Patent Owner's Demonstrative Exhibit
572018-05-14Potential Patent OwnerOtherObjections to Petitioner's Demonstratives
582018-05-17Potential Patent OwnerMotion to TerminateJoint Motion to Terminate Proceedings
592018-05-17Potential Patent OwnerOtherJoint Request to File Settlement as BCI
602018-05-21BoardFinal DecisionTermination Decision Document
612018-05-24Potential Patent OwnerOtherMotion to Expunge
622018-05-29BoardOtherGranting Patent Owner's Motion to Expunge
Grounds Asserted

Not a member? Sign up for free!